Future studies will determine if vitamin C can also improve the response of TNBC to other PI3K inhibitors, especially alpelisib, which was recently approved by the FDA to treat PIK3CA-mutated HR+/HER2- breast cancer and is under evaluation in ongoing TNBC clinical trials. Here, HR is linked to breast cancer.